Home > Boards > Free Zone > Health and Sciences > Biotech Values

if sales of the AG tail off or

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
acgood Member Profile
 
Followed By 18
Posts 1,105
Boards Moderated 0
Alias Born 05/12/07
160x600 placeholder
Top Company News of the Day
The FDA's authorization expands the drug's use to fight Covid-19 to people under the age of 12.
Soybeans Futures Higher on Export Hopes - Daily Grain Highlights
FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infants
Front Month Nymex Natural Gas Fell 24.56% This Week to Settle at $4.1320 -- Data Talk
Front Month Nymex RBOB Gasoline Fell 1.42% This Week to Settle at $1.9529 -- Data Talk
Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19
Trade Deficit, Consumer Prices on Deck -- Data Week Ahead
Sportsman's Warehouse Shares Fall 19% After Takeover Deal Terminated
EURO STOXX 50 Index Ends the Week 0.23% Lower at 4080.15 -- Data Talk
FTSE 100 Index Ends the Week 1.11% Higher at 7122.32 -- Data Talk
DAX Ends the Week 0.57% Lower at 15169.98 -- Data Talk
CAC 40 Index Ends the Week 0.38% Higher at 6765.52 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.20% Higher at 3613.81 -- Data Talk
STOXX Europe 600 Index Ends the Week 0.28% Lower at 462.77 -- Data Talk
FTSE Closes Down Amid Persistent Growth Fears
Roche to Name New Member to Board of Directors, Re-Elect Chairman
Adobe Down Over 6%, On Pace for Largest Percent Decrease Since March 2020 -- Data Talk
U.S. Services Sector Growth Accelerated to New Record-High in November -- ISM
U.S. Services Sector Growth Cooled Slightly in November -- IHS Markit
FTSE Edges Higher, Wickes's Margin Outperformance Leads to Further Upgrades
U.S. Nonfarm Payrolls Up 210K in November, Unemployment Rate 4.2% -- Update
Johnson & Johnson's Janssen Says Psoriatic Arthritis Trial Meets Objective
Bostic Wants to Speed Up Fed's Asset Buying Taper; Quarles Says Fed Will Need to Raise Rates
U.S. Nonfarm Payrolls Up 210K in November, Unemployment Rate 4.2%
Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
FTSE Edges Higher, Service Sector Kept Growth Momentum in November
acgood   Tuesday, 10/25/11 09:15:21 PM
Re: DewDiligence post# 129384
Post # of 240623 
Quote:
if sales of the AG tail off or go to zero, the threshold at which NVS’ Lovenox sales in a given launch year switch into 45%-profit-share mode (rather than royalty mode) also decreases



Have you obtained color on this from management or other sources? I am trying to reconcile your comment above, the language in the press release, and the language in the redacted license agreement.

From the press release:

Quote:
Going forward, if the authorized generic is the only marketed generic Lovenox, at the start of each subsequent product year, Sandoz is obligated to pay to Momenta a 10-12% royalty on net sales of enoxaparin sodium until the contractual profit reaches $135.0 million. Thereafter, for the balance of the product year, Sandoz is obligated to pay Momenta a 45% profit share



Quote:
1.7. "AVENTIS [**]". Aventis [**] means [*$135m**] Dollars (U.S.$[**]); PROVIDED, HOWEVER, THAT, if the Aventis [**] begins on a day after the first day of a Post-Launch Year, the Aventis [**] for the remainder of such Post-Launch Year shall equal the product of (a) the number of days between (and including) the date of such termination of the [*Sole generic period*] until the end of such Post-Launch Year, multiplied by (b) the quotient of (i) U.S.$[*$135m*] divided by (ii) 365 (ie, $99.1m for 10/5/2011** thru 6/30/2011).



*The language implies an inflexible dollar amount, not an amount that moves based on AG sales levels

**99.1/135 corresponds prorated 268 days (puts the SNY AG launch on or around 10/5/2011)


Quote:
4.8.1 If the [*Sole Generic Period*] Period (i) terminates because there is [*An authorized generic on market*], or (ii) never existed as a result of [**]; then (subject to the provisions of Section 4.9) thereafter until such time as there is [**] (the "Aventis [**]"), at which time the provisions of Section 4.6 or Section 4.7, as applicable, shall govern, Sandoz shall pay the Post-[*third party generic entrant*] Royalty during each Post-Launch Year (or portion thereof) until such time as the total Profits for the Product in the U.S. Territory for such Post-Launch Year (or portion thereof) equal the Aventis [**]($135m), and thereafter, solely with respect to any Profits exceeding the Aventis
[**]($135m), during the remainder of such Post-Launch Year, Sandoz shall pay Momenta the Profit Interest (45%) with respect to such excess. The Aventis [**] shall automatically terminate upon the existence of [*third party generic entrant*] in the U.S. Territory and the provisions of this Section 4.8 shall not apply thereafter.
4.8.2 The amounts payable under Section 4.8.1 shall be adjusted pursuant to SCHEDULE 4.3***



*** The Schedule 4.3 pertains to the "true-up" accounting between Sandoz and MNTA for cost-sharing, no mention of any SNY sales figures.

I don't see anything from all this that suggests the $135m is flexible year to year.

Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences